Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder. The debilitating choreic movements that plague HD patients have been attributed to striatal degeneration induced by the loss of cortically supplied brain-derived neurotrophic factor (BDNF). Here, we show that in mouse models of early symptomatic HD, BDNF delivery to the striatum and its activation of tyrosine-related kinase B (TrkB) receptors were normal. However, in striatal neurons responsible for movement suppression, TrkB receptors failed to properly engage postsynaptic signaling mechanisms controlling the induction of potentiation at corticostriatal synapses. Plasticity was rescued by inhibiting p75 neurotrophin receptor (p75 NTR ) signaling or its downstream target phosphatase-and-tensin-homolog-deletedon-chromosome-10 (PTEN). Thus, corticostriatal synaptic dysfunction early in HD is attributable to a correctable defect in the response to BDNF, not its delivery.
INTRODUCTION
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder resulting from a CAG expansion in the huntingtin gene (The Huntington's Disease Collaborative Research Group, 1993) . The earliest signs of pathology in HD are in the striatum (Menalled and Chesselet, 2002; Raymond et al., 2011) , a subcortical structure involved in the control of movement and action selection (Gerfen and Surmeier, 2011) . The striatum exerts this control by transforming excitatory synaptic input from the cerebral cortex into patterned activity in two parallel projection systems: so-called direct and indirect pathways. Activity in direct pathway spiny projection neurons (dSPNs) promotes action, whereas activity in indirect pathway spiny projection neurons (iSPNs) suppresses action (Gerfen and Surmeier, 2011) . A deficit in the ability of cortical circuits to drive iSPNs has long been hypothesized to underlie unwanted movement in the early stages of HD (Zuccato et al., 2010) . In recent years, this loss has been attributed to impaired expression and release of brain-derived neurotrophic factor (BDNF) by corticostriatal terminals (Gauthier et al., 2004; Zuccato and Cattaneo, 2007) .
To gain a better mechanistic grasp of how alterations in BDNF signaling might selectively affect how iSPNs translate cortical inputs, the corticostriatal network was studied in brain slices from hemizygous BACHD mice crossed with reporter lines for dSPNs and iSPNs Gerfen and Surmeier, 2011; Gray et al., 2008) . The BACHD mouse is a transgenic model of HD in which the full-length human mutant huntingtin (mHtt) gene has been inserted using a bacterial artificial chromosome (BAC) (Gray et al., 2008) . These mice display progressive motor and physiological deficits that are pronounced by 6 months of age Gray et al., 2008) . To our surprise, striatal levels of BDNF and messenger RNA (mRNA) for its receptorthe TrkB receptor (TrkBR)-appeared normal in symptomatic BACHD mice. This also was true in the Q175 knockin mouse model of HD, which displays a similar progressive motor and physiological phenotype (Menalled et al., 2012; Heikkinen et al., 2012) . Moreover, activity-dependent phosphorylation of TrkBRs-the first step in postsynaptic BDNF signaling-was normal in striata from 6-month-old BACHD mice. However, downstream TrkBR signaling through Akt was significantly impaired. This deficit was attributable to upregulation in the expression of phosphatase-and-tensin-homolog-deleted-onchromosome-10 (PTEN) and amplification of BDNF signaling through p75 neurotrophic receptor (p75 NTR )-a well known inhibitor of TrkBR signaling (Song et al., 2010) .
RESULTS

BDNF Expression and Delivery to the Striatum Was Normal in HD Mice
At the outset of our study, the expression of BDNF mRNA in the cortex of BACHD and Q175 heterozygous knockin mice was assessed using quantitative PCR (qPCR). In contrast to the original description of these mice (Gray et al., 2008) , we found no evidence of reduced abundance of cortical BDNF mRNA in BACHD mice at either 2 or 6 months of age, nor did we find any evidence of reduced BDNF protein levels in either the cortex or striatum (Figures 1A-1C ; Figure S1A available online). To determine if this was peculiar to this HD model, we examined 6-month-old heterozygous Q175 knockin mice, but again, no reduction in cortical BDNF mRNA expression was found (Figure 1D) . Several previously published qPCR primer sets were examined to ensure that our results were not simply a consequence of primer choice or poor amplification efficiency. All of them yielded similar results. One possible explanation for the discrepancy is that previous work relied on a single, highly variable ''reference gene'' for normalization of transcript abundance rather than a weighted average of several more stable transcripts (Pfister et al., 2011) (Figure 1 ; Figure S1D and Table S1 ).
Although its cortical and striatal levels were not reduced in the HD models, BDNF release from cortical terminals and activation of postsynaptic TrkBRs could be impaired (Gauthier et al., 2004) . To test this idea, two assays were performed. First, qPCR was used to assess the expression of full-length or truncated TrkBR mRNA in iSPNs and dSPNs isolated by fluorescence-activated cell sorting (FACS) . No change in TrkBR expression was found in either type of SPN in symptomatic (5-6 months old) BACHD mice ( Figure S1C ). Next, depolarization-induced phosphorylation of striatal TrkBRs was used as an assay of BDNF release and receptor binding. Modest depolarization of wild-type (WT) brain slices by incubation in elevated extracellular KCl (17 mM) for 10 min significantly increased phophorylation of striatal TrkBRs (Figure 2A ). However, TrkBR phosphorylation induced by depolarization was identical in 6-to 9-month-old WT and BACHD mice ( Figure 2B ).
Taken together, our data suggest that, in relatively young but symptomatic BACHD and heterozygous Q175 mice, cortical production of BDNF, its delivery to the striatum, and its ability to bind and activate striatal TrkBRs were normal. Therefore, if there is indeed a BDNF signaling defect in HD, it must be downstream of TrkBRs at this age.
TrkBR Signaling Can Be Assessed with Cellular Resolution
To test the hypothesis that TrkBR signaling was impaired, one of its targets-Akt-was examined following induction of BDNF release by depolarizing ex vivo brain slices. Indeed, the ratio of Neuron Impaired TrkBR Signaling in Huntington's Disease phosphorylated Akt to total striatal Akt was significantly lower in brain slices from BACHD mice than in those from WT mice following circuit-level depolarization ( Figure 2C ), suggesting there was an HD-related deficit in TrkBR signaling. To help pinpoint the cellular site of this signaling deficit, RNA sequencing (RNA-seq) was performed on mRNA from 5-to 6-month-old BACHD dSPNs and iSPNs that had been isolated by FACS ( Figure S2 ; Tables S2 and S3) . These data were then used to predict alterations in signaling networks in HD iSPNs and dSPNs. The top signaling network identified by this analysis was the huntingtin network in both iSPNs and dSPNs (data not shown).
The next most prominently altered network was that of BDNF. It is interesting that the BDNF signaling network was diminished in BACHD iSPNs but elevated in dSPNs ( Figures S2A and S2B ). Not only does this analysis suggest that the BDNF/TrkBR signaling deficit is specific to iSPNs at this age, but it also confirms the inference that there is not a general deficit in BDNF delivery to the striatum. To unequivocally ascertain whether TrkBR signaling was impaired in SPNs, another assay was needed. Previous work had shown that corticostriatal long-term potentiation (LTP) in SPNs required BDNF activation of postsynaptic TrkBRs (Jia et al., 2010) . This form of synaptic plasticity is postsynaptically induced and expressed, making it an ideal assay of postsynaptic TrkBR signaling.
Although necessary, TrkBRs are not sufficient to induce LTP at corticostriatal synapses. Postsynaptic N-methyl-D-aspartate (NMDA) receptors (NMDARs) and G protein coupled receptors (GPCRs) linked to activation of protein kinase A (PKA) also are necessary for LTP induction (Calabresi et al., 2007; Kreitzer and Malenka, 2008; Shen et al., 2008) . In iSPNs, the obligate GPCRs are adenosine A2a receptors (A2aRs). Coactivating these three signaling pathways-TrkBR, NMDAR, and A2aR-should lead to postsynaptically induced LTP in SPNs, which could be measured using two-photon uncaging of glutamate on dendritic spines, creating a bioassay with cellular resolution. To this end, SPNs were voltage clamped at À90 mV in the presence of pharmacological activators of TrkBRs (BDNF, 50 ng/ml), A2aRs (CGS21680, 200 nM), and NMDARs (NMDA, 5 mM). To prevent active propagation of activity and indirect effects on the striatal network, the Na + channel blocker tetrodotoxin (1 mM) was bath applied. At À90 mV, NMDARs are blocked by Mg
2+
. To transiently unblock them and trigger LTP induction, SPNs were depolarized four times to +20 mV for 1 s, resting 10 s between depolarizations ( Figure S3A ). This cell-specific induction paradigm produced a significant, long-lasting enhancement in postsynaptic glutamate receptor currents at about one-third of the spines examined using two-photon laser uncaging of glutamate (Figures 3A-3F ; Figures S3B and S3C) . Coactivation of all three postsynaptic signaling pathways (TrkBR, NMDAR, and A2aR) was necessary to induce potentiation of uncaging-evoked excitatory postsynaptic currents (uEPSCs), as disrupting any one signaling pathway (blocking BNDF signaling through TrkBRs with 150 nM K252a or scavenging BDNF with 4 mg/ml TrkB-Fc; blocking NMDARs with 50 mM AP5; blocking A2aRs with 200 nM SCH58261) resulted in the attenuation or loss of potentiation ( Figure 3F ). In dSPNs, this protocol also worked when the A2aR agonist was replaced with a D1 receptor agonist ( Figure 3G ). Both extracellular signal-regulated kinase (ERK) and phosphoinositide-3 kinase (PI3K), which are known to be activated by TrkBRs, were necessary to induce potentiation, as it was blocked by antagonizing either one ( Figure 3F ). Most important, this provided a bioassay for TrkBR signaling with the level of resolution needed.
As cortical pyramidal neurons that project to the striatum release BDNF, but thalamic neurons that project to the striatum do not (Altar et al., 1997) , it was our working hypothesis that BDNF-dependent synaptic potentiation was limited to corticostriatal synapses. To test this hypothesis, a channelrhodopsin 2 (ChR2) expression construct was virally delivered to sensorimotor cortex pyramidal neurons or to intralaminar thalamic neurons that project to the striatum. Two weeks after infection, brain slices were prepared, and the responses of individual SPN spines to adjacent ChR2 stimulation with a fixed minimal diameter (approximately 1 mm) 473 nm blue laser were assayed in the presence of 1 mM tetrodotoxin (TTX) and 100 mM 4-aminopyridine (4-AP) (Petreanu et al., 2009 ). In the region of the striatum most closely linked to sensorimotor cortex, about 70% of iSPN spines on distal dendrites (>100 mm from the soma) were responsive to ChR2 stimulation in the cortically transduced mice (48 of 68 spines). In this same region, about 30% (32 of 115) of iSPN spines in distal dendrites were responsive to ChR2 stimulation in thalamically transduced mice. At corticostriatal synapses, the probability of inducing synaptic potentiation was similar to that seen previously ( Figure 3H ). In contrast, at thalamostriatal synapses, the median probability of potentiation was zero (Figure 3H) . Plasticity also was examined in SPNs from transgenic mice expressing ChR2 in cortical, but not in thalamic, neurons (Arenkiel et al., 2007) . In these mice, potentiation was induced in roughly half the connected spines ( Figure 3H ), consistent with it being a corticostriatal phenomenon.
BDNF-Dependent Postsynaptic Plasticity Was Lost in BACHD and Q175 iSPNs
To appraise the integrity of TrkBR signaling in SPNs expressing mHtt, synaptic potentiation was examined in brain slices from BACHD mice crossed into the SPN reporter lines ( Figure 4A ). In slices from the brains of mice that were 6-8 months of age-a time before frank cell loss (Gray et al., 2008) or gross dendritic atrophy ( Figure S4 ), but a time when there are clear motor symptoms-uEPSC potentiation in dSPNs was normal ( Figure 4B ). However, in iSPNs, potentiation was effectively lost ( Figure 4C ). In younger (2-3 months old) BACHD mice, uEPSC potentiation in iSPNs was reduced but not lost (Figure S5A) , suggesting that the impairment was progressive. Furthermore, the impairment in synaptic plasticity was not unique to this HD model, as iSPNs from 6-month-old heterozygous Q175 knockin mice had the same deficit ( Figure 4D ).
To verify that the plasticity deficit in HD neurons also was present when corticostriatal terminals were engaged, a conventional high-frequency stimulation (HFS) LTP induction protocol was tested (Calabresi et al., 2007; Jia et al., 2010) . In this protocol, BDNF release was induced by electrical stimulation of corticostriatal axons. In WT iSPNs, this protocol induced a robust LTP ( Figure 4E) ; however, the same induction protocol failed to induce LTP in iSPNs from 6-month-old BACHD mice ( Figure 4E ; baseline EPSP amplitude was 3.01 ± 0.72 mV in WT iSPNs and 4.06 ± 1.11 mV in BACHD iSPNs, p = 0.4286, Mann-Whitney nonparametric test). These results are consistent with those of a previous study suggesting that LTP, as measured with field potential recordings, is reduced in the striatum of rapidly progressing R6/2 HD mice (Kung et al., 2007) . Although these experiments do not unequivocally demonstrate a synaptic locus for the HD deficit, they are consistent with the impairment seen in isolated, voltage-clamped spines.
A deficit in the ability to induce LTP should lead to both a reduction in the number of glutamate receptors at corticostriatal synapses and a decrease in dendritic spine density. To test these predictions, corticostriatal miniature excitatory postsynaptic currents (mEPSCs) were measured following electrical stimulation of cortical afferent fibers in the presence of Sr . As predicted, the amplitude of mEPSCs was reduced at corticostriatal synapses on iSPNs (but not dSPNs) in brain slices from 6-month-old BACHD mice ( Figure 4F ). Although there was no change in total dendritic length (Figure S4C) , dendritic spine density was reduced in iSPNs (but not dSPNs) from 6-month-old BACHD mice ( Figure 4G ). Thus, the deficit in LTP induction was paralleled by structural adaptations in HD iSPNs. What was responsible for the LTP deficit in iSPNs expressing mHtt? Previous work has demonstrated that ifenprodil-sensitive extrasynaptic NMDARs increase in SPNs in the YAC128 mouse model of HD (Milnerwood et al., 2010) . The situation was similar in BACHD iSPNs. As in the YAC128 iSPNs, the ratio of corticostriatal synaptic NMDAR to AMPAR currents was not altered in BACHD iSPNs; however, in the presence of the glutamate transport blocker DL-threo-b-benzyloxyaspartic acid (allowing the engagement of extrasynaptic receptors), the NMDAR component was greater in BACHD than WT iSPNs (Figures S5B and S5C) . 2PLUG experiments on distal spines of iSPNs corroborated this result ( Figure S5D ). Acute ifenprodil application did not restore uEPSC potentiation in iSPNs from BACHD mice, nor did it eliminate uEPSC potentiation in WT iSPNs ( Figures S5E and S5F ). However, our data do not exclude the possibility that sustained activation of extrasynaptic NMDARs-over days or weeks-triggers adaptations that underlie the synaptic deficit in HD models. (Minichiello et al., 2002) . In addition to activating TrkBRs, BDNF also can robustly activate p75 NTRs , albeit less potently (Bothwell, 1995; Zhang et al., 2008) . The concentration of BDNF used to mimic synaptic release in our experiments was near the IC 50 of p75 NTR s (Bothwell, 1995) . Furthermore, although developmentally downregulated (Dechant and Barde, 2002 ), p75 NTR s continue to be expressed at low levels in adult SPNs from both WT and BACHD mice ( Figures S5G and S5H ) and have recently been implicated in HD pathology (Brito et al., 2013) . To test for their involvement, p75 NTR expression was knocked down by viral delivery of a small hairpin RNA (shRNA) (Figure S5I) . Indeed, knockdown of p75 NTR expression fully restored BDNF-dependent synaptic potentiation in BACHD iSPNs ( Figure 5A ).
To provide an additional test of p75 NTR involvement, the effects of inhibiting its signaling partners were examined. p75 NTR interacts directly with the Rho GDP dissociation inhibitor (Rho-GDI), which controls activation of the small GTPase RhoA (Yamashita and Tohyama, 2003) . RhoA, in turn, activates Rho-associated kinase (ROCK), which phosphorylates and activates PTEN (Yang and Kim, 2012) . PTEN dephosphorylates phosphoinositide products of PI3K, blunting its signaling (Song et al., 2010) . As shown earlier, PI3K signaling is necessary for TrkBR-induced uEPSC potentiation. To test for the involvement of Rho-GDI, we incubated slices with a TAT peptide targeting its interaction domain with p75 NTR (referred to as ''Pep5'' by Yamashita and Tohyama) (Ilag et al., 1999; Yamashita and Tohyama, 2003) ; Pep5 rescued BDNF potentiation in BACHD iSPNs (Figure 5A) . Next, ROCK, the target of RhoA, was inhibited with Y-27632 (10 mM); this also rescued potentiation ( Figure 5A ). Last, PTEN was targeted; either pharmacologically inhibiting PTEN with dipotassium bisperoxo(picolinato)oxovanadate (PTP Inhibitor XV bpV(pic), 5 mM) or knocking down its expression with a virally delivered shRNA rescued potentiation measured by both 2PLUG ( Figure 5A ) and electrical stimulation ( Figure 5C ). These results clearly point to p75 NTR signaling through PTEN as responsible for disrupting TrkBR signaling in HD iSPNs. This signaling pathway is also present in WT iSPNs; however, pharmacological inhibition of PTEN had no effect on synaptic potentiation in WT iSPNs or dSPNs ( Figure S5J ). What was different in HD iSPNs? The expression of p75 NTR mRNA was not measurably different in iSPNs isolated by FACS from HD striata ( Figures  S5G and S5H) . However, the expression of PTEN was significantly elevated in BACHD iSPNs, but not dSPNs ( Figure 5B ), providing a mechanistic foundation for the enhancement of p75 NTR signaling.
If the HD deficit in TrkBR signaling is simply a consequence of BDNF coactivation of p75 NTR , then the signaling of growth factors that do not bind to p75 NTR should be unaffected. In SPNs, fibroblast growth factor (FGF) binds to receptors that, like TrkBRs, are tyrosine kinase receptors that promote LTP induction (Eswarakumar et al., 2005; Flajolet et al., 2008) . Replacing BDNF with FGF (20 ng/ml) led to normal synaptic potentiation in 6-to 8-month-old BACHD iSPNs ( Figure 5D ). Quantitative profiling of iSPN mRNA from 6-month-old BACHD mice revealed that FGF receptor 1 (FGFR1) mRNA expression was elevated compared to controls ( Figure 5E ; Figure S5K ), suggesting that FGFRs were part of an attempt to compensate for the TrkBR signaling deficit.
DISCUSSION
For the past decade, the striatal pathology in HD has been attributed to a decrease in cortical BDNF delivery (Gauthier et al., Zhang et al., 2003; Zuccato et al., 2001; Zuccato and Cattaneo, 2007) . As a consequence, BDNF replacement has been viewed as a promising approach for slowing disease progression (Canals et al., 2004; Zuccato and Cattaneo, 2007) . Although it does not exclude the possibility that, later in the progression of the disease, such trafficking deficits manifest themselves, our work argues that deficits in TrkBR and p75 NTR signaling precede them.
A cornerstone of the BDNF delivery hypothesis has been the apparent drop in cortical BDNF mRNA expression in young HD mouse models. In our hands, there was no evidence of decreased cortical BDNF expression in either BACHD or heterozygous Q175 mice at 6 months of age-a time point at which behavioral and physiological deficits are evident Gray et al., 2008) . The discrepancy between our results and previous ones did not stem from primer design, as a variety of published and unpublished primer sets yielded the same result. However, the discrepancy could be due to differences in the way transcript abundance was estimated. For qPCR, an internal standard is necessary to correct the threshold cycle number for variation in the amount of starting material. Commonly, a ''reference gene'' is used for this purpose that is assumed to be unaffected by the experimental intervention being examined. Beta-actin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcripts often are used for this purpose, as in the previous studies of BDNF abundance (see Table S1 ). However, these two transcripts are not ideal standards, because of variability in their expression ( Figure S1 ). A more appropriate strategy is to use a weighted average of several stable transcripts to derive a standard. Doing this led to the conclusion that there was no change in BDNF mRNA levels in cerebral cortex of BACHD and heterozygous Q175 HD models. In agreement with this conclusion, the phosphorylation of striatal TrkBRs in response to depolarization-induced release of BDNF by cortical terminals was normal in tissue from BACHD mice.
It is worth noting, however, that in 6-month-old homozygous Q175 knockin mice, there was a significant decrease in cortical BDNF expression ( Figure S1B ), in agreement with the assertion that mHtt can regulate BDNF expression when expressed at high enough levels (Canals et al., 2004) . However, because of the more rapid disease progression in these mice (Menalled et al., 2012; Heikkinen et al., 2012) comparisons to the BACHD model are problematic. Moreover, the relevance of this gene-dose effect to the human condition is uncertain (Wexler et al., 1987) .
In spite of there being no detectable change in cortical BDNF expression or striatal delivery in early-stage HD models, there was a clear deficit in the postsynaptic response of iSPNs to BDNF. To unequivocally assay postsynaptic TrkBR signaling in a single, phenotypically defined neuron, a strategy for inducing synaptic potentiation at visualized spines that did not depend on activation of presynaptic fibers was developed. Unlike synaptic potentiation at other synapses (Harvey and Svoboda, 2007; Tanaka et al., 2008) , corticostriatal long-term synaptic potentiation requires coactivation of three synaptic or perisynaptic proteins: TrkBRs, NMDARs, and a G olf coupled receptor (A2aRs or D1Rs, depending on SPN type) (Calabresi et al., 2007; Jia et al., 2010; Shen et al., 2008) . There is no requirement for presynaptic activity other than to release the agonists for these receptors. The only postsynaptic induction requirement (beyond intracellular signaling) is membrane depolarization to relieve the Mg 2+ block of NMDARs. In the presence of agonists for these three receptors, four brief postsynaptic depolarizations (to open NMDARs) were all that was required to produce lasting potentiation of axospinous, corticostriatal synapses, as judged by focal uncaging of glutamate on spine heads or optogenetic stimulation of corticostriatal terminals. Our study (see Figure 3) demonstrates not only the factors necessary for induction of corticostriatal potentiation but what is sufficient for induction. The ability to induce corticostriatal synaptic potentiation using this protocol or with a conventional HFS protocol was lost specifically in iSPNs from BACHD and heterozygous Q175 mice. Potentiation was normal in dSPNs. In BACHD iSPNs, there were two structural correlates of the deficit. One was a reduction in the average number of postsynaptic AMPARs, as estimated by the amplitude of corticostriatal mEPSCs at membrane potentials that were not permissive for NMDAR currents. The other was a reduction in spine density. Both observations are consistent with previous work suggesting that potentiated axospinous synapses not only have more synaptic AMPARs but are also more stable (Kasai et al., 2010; Kopec et al., 2006; Mendez et al., 2010) .
This cell-specific deficit in potentiation was attributable to upregulation of p75 NTR signaling through PTEN, resulting in impaired TrkBR activation of PI3K and Akt. Striatal p75 NTR signaling is elevated in other HD models (Brito et al., 2013) , buttressing this conclusion. Both pharmacological and molecular approaches supported this conclusion. Either decreasing p75 NTR expression or blocking its coupling to RhoA normalized TrkBR signaling. Antagonizing the target of RhoA, ROCK, also corrected TrkBR signaling. Either decreasing PTEN expression with a shRNA or pharmacologically diminishing its activity restored TrkBR signaling. The alteration in p75 NTR signaling in HD iSPNs was attributable to the upregulation of PTEN, not p75 NTR itself. Why PTEN was upregulated is unclear. It is possible that PTEN trafficking is altered by mHtt, leading to alterations in expression and function (Gericke et al., 2006) .
One additional piece of evidence in support of the involvement of p75 NTR signaling was the finding that synaptic potentiation was restored in HD iSPNs by FGF. FGFRs expressed by iSPNs have previously been shown to promote the induction of corticostriatal synaptic potentiation through mechanisms similar to those of TrkBRs . However, unlike BDNF, FGF does not bind to p75 NTR . Thus, astrocyte release of FGF (Tooyama et al., 1993) and FGFR signaling might partially compensate for the loss of trophic support derived from BDNF.
Our results also are concordant with work implicating Ras Homolog Enriched in Striatum (Rhes) in HD pathogenesis (Subramaniam et al., 2009) . Rhes inhibits Akt signaling , and the elimination of Rhes increases Akt phosphorylation and diminishes the impact of mHtt Harrison and Lahoste, 2013) . Moreover, extrasynaptic NMDAR signaling, which is upregulated in SPNs of HD models (Milnerwood et al., 2010) , increases Rhes expression (Okamoto et al., 2009 ). Thus, extrasynaptic NMDAR signaling through Rhes and p75 NTR signaling through PTEN might synergize to suppress Neuron Impaired TrkBR Signaling in Huntington's Disease Akt signaling, which is known to be necessary for neuronal vitality (Humbert et al., 2002) .
Diminished innervation of iSPNs, the anchors of the basal ganglia circuitry responsible for motor suppression, can provide a straightforward explanation for early hyperkinetic HD motor symptoms (Gerfen and Surmeier, 2011; Menalled and Chesselet, 2002; Raymond et al., 2011) . Although this behavior may not be fully manifest in rodent models at this age, complete removal of TrkBR signaling in iSPNs leads to hyperlocomotion in otherwise normal mice (Besusso et al., 2013) . This deficit could, in turn, trigger adaptations throughout the neural network linking the striatum and cortex (Kozorovitskiy et al., 2012) , resulting in cortical pathology associated with HD (Cepeda et al., 2007) . It also is possible that enhanced p75 NTR signaling in the cerebral cortex induces pathology, as deficits in TrkBR signalingwhether in the striatum or cortex-have profound effects on neuronal function, as well as mHtt toxicity (Humbert et al., 2002; Warby et al., 2005) . While, in our slice preparation, p75 NTR activation is likely achieved by BDNF, it should be noted that other ligands (such as proNGF or proBDNF) may contribute to p75 NTR engagement in vivo (Dechant and Barde, 2002; Fayard et al., 2005; Song et al., 2010) . Although it is unlikely that all of the pathology in HD can traced to a single cause, our studies strongly suggest that, in the early stages of the disease, p75 NTR antagonism should be part of an effective therapeutic strategy for restoring normal BDNF and Akt signaling. Moreover, given that its tissue distribution narrows and expression level falls with development (Dechant and Barde, 2002) , p75 NTR antagonism should be less likely to have unacceptable side effects in adult HD patients than strategies targeting TrkBRs, which continue to be robustly and widely expressed in the adult brain.
EXPERIMENTAL PROCEDURES
Electrophysiology Parasagittal brain slices (275 mm) were prepared from D 2 BAC-EGFP (FVB), Thy1-ChR2 (C57BL/6), BACHD (FVB) x D 2 BAC-EGFP (FVB), BACHD (FVB) x D 1 BAC-EGFP (FVB), or Q175 (C57BL/6) transgenic mice following procedures approved by the Northwestern University Animal Care and Use Committee, as described elsewhere (Day et al., 2008) . Patch pipettes were loaded with internal recording solution containing (in millimolar): 120 CsMeSO 3 , 5 NaCl, 10 tetraethylammonium-Cl (TEA-Cl), 10 HEPES, 5 Qx-314, 4 Mg-ATP, 0.3 Na-GTP, 0.2 Fluo-4 pentapotassium salt, and 0.05 Alexa Fluor 568 hydrazide sodium salt (Invitrogen), pH 7.25; osmolality, 270-280 mOsm À1 . Slices were transferred to a submersion-style recording chamber on a fixed-stage Olympus BX51 upright microscope and perfused with 95%O 2 /5%CO 2 -bubbled artificial cerebrospinal fluid (ACSF) containing (in millimolar): 124 NaCl, 3 KCl, 2 CaCl 2 , 1 MgCl 2 , 26 NaHCO 3 , 1 NaH 2 PO 4 , and 16.66 glucose. Electrophysiological recordings were made using a Multiclamp 700B amplifier; protocols were delivered and recorded using the custom-written freeware package WinFluor (John Dempster, Strathclyde University), as described elsewhere (Day et al., 2008; Plotkin et al., 2011) . Recordings were performed at room temperature and filtered at 1 kHz. Strontium-mediated asynchronous miniature EPSC amplitudes (2 mM Sr 2+ in external recording solution) were measured as previously described using an internal recording solution composed of (in millimolar): 120 CsMeSO 3 , 15 CsCl, 8 NaCl, 10 TEA-Cl, 10 HEPES, 2-5 Qx-314, 0.2 EGTA, 2 Mg-ATP, and 0.3 Na-GTP (Ding et al., 2008) .
Single Spine Synaptic Potentiation
SPNs were held at À90 mV in the presence of an ''LTP cocktail'' containing 50 ng/ml BDNF, 5 mM NMDA, 5 mM glycine, 1 mM TTX, 200 nM CGS21680, 1 mM sulpiride, 2 mM muscarine, 50 mM CPCCOEt, 1 mM MPEP, and 0.1% BSA, dissolved in HEPES-buffered ACSF, unless otherwise stated. In experiments performed in dSPNs, CGS21680 was replaced with 5 mM 6-Chloro-PB hydrobromide and 0.1% sodium metabisulfite. Muscarine had no detectable effect on LTP induction and was thus omitted in most cases (in all compared groups). This LTP cocktail was superfused (0.4 ml/hr) over the slice using a syringe pump and multibarreled perfusion manifold (Cell MicroControls). Baseline uEPSCs were recorded from approximately eight coplanar distal (greater than 90 mm from soma) spines, separated by 200 ms, and averaged three to eight times (5 s intertrial interval). The cell was then stepped from À90 to 20 mV for 1 s, four times total, 10 s between steps. uEPSCs were then measured from the same spines in the same manner 10-30 min after the depolarizing voltage steps. Unless otherwise indicated, represented time points are 10-15 min postinduction. Potentiation was defined as an increase in EPSC amplitude of at least 150% of baseline (based on Figure 1D ; Figure S5 ). Series resistance was monitored, and recordings with a change of more than 20% were rejected from analysis.
Two-Photon Laser Scanning Microscopy, Two-Photon Laser Uncaging, and ChR2 Stimulation dSPNs and iSPNs were identified by somatic EGFP expression using two-photon excited fluorescence, which was induced and detected using a Prairie Ultima laser scanning microscope system (Prairie Technologies). Fluorescent and bright-field images were viewed in register using a Dodt contrast detector system. Cells were patched using video microscopy with a Hitachi CCD camera and an Olympus 603/1.0 NA lens. Green (EGFP) and red (Alexa Fluor 568) signals were acquired using 810 nm excitation (Verdi/Mira laser). Following patch rupture, the internal solution was allowed to equilibrate for 10-15 min before imaging. High-magnification z series were acquired with 0.072 mm 2 pixels, with 4 ms dwell time and 0.3 mm z-steps. At the end of each experiment, whole-cell z series were acquired with 0.36 mm 2 pixels, with 10 ms dwell times and 1 mm z-steps. Glutamate uncaging was achieved using a Chameleon-XR laser system (Coherent Laser Group). MNI-glutamate (5 mM; Tocris, Cookson) was superfused over the slice through the same syringe used to deliver the LTP cocktail. Glutamate was uncaged adjacent to individual spines using 1 ms pulses of 720 nm light typically 10-20 mW in power at the sample plane. Photolysis power was tuned via a third Pockels cell modulator (Con Optics) to achieve uEPSCs averaging 5-15 pA. ChR2 stimulation was achieved with a Prairie Instruments blue laser (473 nm) and shuttered to a minimal fixed diameter (approximately 1 mm). Presynaptic terminals adjacent to individual distal spines were targeted. All ChR2 studies were performed in the presence of 1 mM TTX, 100 mM 4-AP, and the LTP cocktail.
Electrical LTP Induction iSPNs from parasagittal 6-to 7-month-old WT and BACHD mice were patched with electrodes containing (in millimolar): 135 KMeSO 4 , 5 KCl, 0.5 CaCl 2 , 10 HEPES, 2 ATP-Mg, 0.5 GTP-Na, 5 phosphocreatine-Tris, 5 phosphocreatine-Na, and 0.3 EGTA. Recordings were made in continuously perfused oxygenated Mg 2+ -free ACSF containing (in millimolar): 135 NaCl, 2.5
KCl, 25 NaHCO 3 , 1.25 NaH 2 PO 4 , 10 glucose, and 2 CaCl 2 . Electrical stimulation was performed with a parallel bipolar electrode placed in the overlying cortex. The HFS LTP induction protocol was composed of 1 s, 100 Hz trains repeated four times at a 10 s interval and performed as described by others (Jia et al., 2010) . Series resistance was monitored, and recordings with a change of more than 20% were rejected from analysis.
Stereotaxic ChR2 Injections
Stereotaxic injections of adeno-associated viral vector (AAV) carrying genes for ChR2 and mCherry (Addgene 20938) were made in either the sensorimotor cortex or thalamus (encompassing the intralaminar nuclei and parts of the ventral thalamus) of isoflurane-anesthetized 6-week-old D 2 BAC-EGFP mice. The titer was 2 3 10 9 genomic copies per microliter. Mice were allowed to recover for at least 2 weeks postinjection. Post hoc visualization of injection sites was performed in acute slices after recordings.
Gene Expression Profiling qPCR was used to determine the abundance of transcripts of interest with procedures similar to that described elsewhere (Chan et al., 2012 Immunoreactivity was detected with an enhanced chemiluminescent reagent (Advansta) and visualized by a ChemiDoc XRS imager (Bio-Rad). The integrated optical density of the target band was quantified in ImageJ (National Institutes of Health) after background subtraction. The levels of the protein of interest were expressed as a ratio to the relevant loading controls. Dorsal striata of both hemispheres of each animal were combined to equal one sample.
shRNA Knockdown To silence PTEN expression, we created an AAV serotype 2 vector encoding for rat PTEN shRNA (siPTEN). The sense, hinge, and siPTEN sequence used to make the PTEN shRNA was 5 0 -GATCCCCGAGTTCTTCCACAAACAGAA CTTCCTGTCATTCTGTTTGTGGAAGAACTCTTTTTTGGAAT-3 0 . The integrity of construct was verified by sequencing. Vector stocks were prepared by packaging the plasmids into AAV serotype 2 particles using a helper-free plasmid transfection system (Morgenstern et al., 2011) . To silence p75 NTR expression, shRNA oligomers targeting the mouse p75 NTR (NM_033217.3) were created using shRNA design tools. The uniqueness of selected target sequences was confirmed by a National Center for Biotechnology Information (NCBI) blast search. Oligos were synthesized from Integrated DNA Technologies. Three constructs (two shRNA and one control) were createdp75-p233 shRNA (CAAGGAGACATGTTCCACA), p75-p890 shRNA (CGCTGACAA CCTCATTCCT), and (AGGATCAAATTGATAGTAAACC), expressing tdTomato-and were packaged into AAV9 (Virovek). Knockdown of p75 NTR expression was confirmed at the mRNA level by qPCR in PC12 cells. AAVs were stereotaxically injected into the dorsal striatum as described earlier. For p75 NTR injections, both 233 and 890 constructs were coinjected. Mice were allowed to recover for at least 2 months before slice experiments were performed. Infected SPNs were identified by expression of a red fluorescent reporter.
NMDA/AMPA Receptor Ratio Measurements SPNs were voltage clamped with a cesium-based internal recording solution (described earlier in Sr 2+ experiments). Electrically evoked EPSCs were induced as described elsewhere (Ding et al., 2008) . AMPA-receptor-mediated responses were measured as the peak inward current recorded at a holding potential of À70 mV. NMDAR-mediated responses were measured as the amplitude of the outward current 50 ms following the stimulus artifact, at a holding potential of +40 mV. Measurement of EPSC areas in the presence of the glutamate uptake blocker TBOA was performed as described by others (Milnerwood et al., 2010) . uEPSCs were evoked as described in the Results and Experimental Procedures. AMPA and NMDAR components of uEPSCs were measured as described earlier, from holding potentials of À80 mV and +40 mV, respectively.
Dendrite Morphology and Spine Density Analysis
Dendrite morphology was calculated from low-magnification z series of Alexa Fluor 568-filled SPNs described earlier. Acquired image stacks were deconvolved using a 60-to 65-iteration adaptive blind deconvolution algorithm with AutoQuant X software (MediaCybernetics). The deconvolved image stack was then imported into the Imaris data visualization package (Bitplane Scientific Software). Dendrite morphology was analyzed using the filament tracer module and the incorporated Sholl analysis. For spine density measurements, highmagnification images of Alexa Fluor 568 dendrites (approximately 90-120 mm from soma) were obtained as described earlier (pixel size = 0.072 mm 2 ). Maximum intensity projections (MIPs) were created from 0.5 mm z-steps, and spines were manually counted along a dendritic region of known distance.
Immunohistochemistry WT mice were perfused with 4% paraformaldehyde, and 50 mm coronal slices were made through the dorsolateral striatum. Immunohistochemistry was performed on free-floating brain slices using a rabbit polyclonal antiserum made against the intracellular domain of the mouse p75 receptor (1:200 dilution; Millipore) (Huber and Chao, 1995) . Detection was achieved using an Alexa Fluor 488-conjugated anti-rabbit secondary antibody. Slices were mounted on slides using Vectashield mounting medium and visualized on a Fluoview FV10i confocal microscope (Olympus).
RNA-Seq
FACS BACHD iSPNs and dSPNs were pooled from four animals (150,000 cells per animal) to create iSPN and dSPN pools for sequencing. Sequencing was performed using Expression Analysis on an Illumina HiSeq 2000. Paired-end sequencing was performed, four-plexed across lanes, for a total of $38 million 50-mer paired reads per sample. Alignment and quality control (QC) were conducted in Omicsoft using the Omicsoft sequence aligner algorithm (Hu et al., 2012) ; fractions per kilobase of exon per million fragments mapped were then calculated following standard formulas. QC assessment found all samples of high quality both at the RNA quality and alignment mapping levels. For each comparison (BACHD versus WT), significance was assessed using DESeq (Anders and Huber, 2010) using the single replicate protocol of DESeq. The resulting RNA-seq data, p values, and fold changes were submitted to Ingenuity's upstream regulator analysis, and the confidence of identified matches was determined with a Fisher's exact test and connected using Ingenuity's knowledge base.
Statistical Analysis
Differences in volume, uEPSC amplitudes, and mRNA expression were examined using the Mann-Whitney U nonparametric test of significance, unless otherwise stated. Normality was not assumed for comparisons. Data points greater than 1.5 SD from the mean were considered outliers and removed. The percentage of spines that potentiated versus those that did not potentiate in different experimental groups was examined using the Fisher's exact test (or chi-square test if n > 100), with potentiation defined as 150% of baseline (Figure 1D) . Variance is graphically presented as error bars or box-whisker plots. Control and experimental groups were interleaved where possible. Differences were considered statistically significant if p < 0.05.
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